** Eighth-largest shareholder Axa Investment Managers addingto stake in biotech firm BTG Group, backing stock toenter FTSE 100.
** Nigel Thomas, manager of the £4.5 bln Axa Framlington UKSelect Opportunities fund, increasing the fund's exposure tohealthcare through BTG and AstraZeneca.
** "The fund's portfolio was very overweight healthcare, buthaving sold down a holding in Shire we have lost about 4pct from the sector," he says.
** "We are now trying to increase exposure by buying moreAstraZeneca and BTG Group, which is a very successful biotechstock, in the FTSE 250 index but could one day go into the FTSE100."
** Stock on a tear this year, up 85.2 pct against a flatFTSE 250. Chart: http://link.reuters.com/qyw92w
** Held by a number of prominent UK asset managers,including star manager Neil Woodford, with most adding to theirstakes. Chart: http://link.reuters.com/ryw92w
** Thomas has returned 103.3 pct in the last five year,beating the fund's FTSE All Share benchmark return of 71.4 pct,according to its latest factsheet.
** Lost 1.6 pct in last six months compared to benchmarkgain of 1.4 pct. (RM: alasdair.pal.thomsonreuters.com@reuters.net)